Quick Answer
LianBio reported Diluted EPS of $1.02 per share (loss) for fiscal year 2022.
LianBio Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2022 | -$1.02 | +82.1% |
| 2021 | -$5.71 | +50.7% |
| 2020 | -$11.58 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2023 | -$0.22 | -10.0% | -10.0% |
| June 30, 2023 | -$0.20 | +48.7% | +9.1% |
| March 31, 2023 | -$0.22 | +15.4% | -10.0% |
| September 30, 2022 | -$0.20 | +68.3% | +48.7% |
| June 30, 2022 | -$0.39 | +92.0% | -50.0% |
| March 31, 2022 | -$0.26 | +91.4% | +58.7% |
| September 30, 2021 | -$0.63 | — | +87.1% |
| June 30, 2021 | -$4.90 | — | -62.8% |
- LianBio showed an increase of +82.1% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2022 period, LianBio’s diluted eps has grown by 91.2% (from $11.58 per share (loss) to $1.02 per share (loss)).
- The most recent figure is from LianBio’s fiscal year 2022 report (Form 10-K), filed with the SEC on March 28, 2023.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: